6.1. Introduction {#s0010}
=================

6.1.1. Overview {#s0020}
---------------

Parkinson\'s disease (PD) was first described as 'paralysis agitans' by James Parkinson in 1817 ([@bib1910]). Classically, PD refers to progressive parkinsonism due to loss of pigmented aminergic brainstem neurons without an identifiable cause, while 'parkinsonism' refers simply to the syndrome of bradykinesia, resting tremor, rigidity and postural reflex impairment. Over nearly two centuries, Parkinson\'s clinical description has provided the framework for clinical investigations, including epidemiologic ones. More recently, investigations of a few families with genetic parkinsonism have revealed a wide range of clinical and pathological features in persons sharing a single disease‐causing mutation, calling into question the assumptions underlying the strict syndromic classification employed by most studies to date. Whether a similar heterogeneity applies to the common 'idiopathic' disorder is not known. Although our current clinicopathological definition of PD may merit revision, further work is needed to determine what an appropriate new definition should be, and the classical definitions will be used in this discussion.

Descriptions of PD were limited to selected clinical settings until the middle of the 20th century, when several population‐based epidemiologic studies were published ([@bib1360], [@bib0960]). Since then, epidemiologic approaches have been used not only to investigate the population distribution of PD, but also as a way to glean clues as to the cause of this 'idiopathic' disorder. Heredity, infection, toxicant exposure and multifactorial gene--environment interactions have been proposed. Although single genetic or environmental causes have been identified, these explain only a small proportion of all cases ([@bib1560], [@bib1300]). This chapter will provide an overview of this work, beginning with descriptive studies, followed by studies investigating the determinants of PD. Because other chapters in this volume thoroughly address the genetics of PD, this topic will be considered briefly here.

6.1.2. Special considerations for epidemiologic studies {#s0030}
-------------------------------------------------------

Epidemiologic investigations of PD must overcome practical challenges ([Table 6.1](#t0010){ref-type="table"} ). PD is relatively uncommon, and even studies of large populations will find relatively few cases. Therefore, the potential error in any single study may be significant. In analytic studies, this can be particularly problematic if the causes of disease differ across populations. Moreover, to the extent that the cause of PD is multifactorial, large populations will be necessary to test hypotheses involving multiple determinants.Table 6.1Some challenges in the epidemiological study of Parkinson\'s diseaseNo diagnostic test • Examination by expert most reliable • No criterion always predicts pathologyLong preclinical period • Exposure may be years before signsLate‐life disorder • Risk factor identification retrospective • Diagnostic accuracy in relatives poorRelatively rare • Large base population neededNo registries; not reported • 'True' distribution of disease not certain

Identification of the cases of PD within a community is typically not a trivial effort. Population‐based registries of PD are not common, and voluntary registries cannot be assumed to be representative. Because PD is relatively infrequent, a fairly large base population must be surveyed to identify sufficient numbers of cases for a study. In some instances, PD cases can be identified through health service rosters within defined geographic areas or in enumerated populations. In others, cases of PD are sought independently of the health care system, such as through door‐to‐door surveys. While the latter approach is theoretically least likely to exclude cases, the time and cost involved are also greatest using this approach.

Population surveys of PD are further complicated because there is no diagnostic test for PD. Clinical features remain the only way to diagnose PD during life. Clinical diagnostic accuracy can vary with the experience of the practitioner. Essential tremor, for example, may be confused with PD in up to 40% of diagnoses in some settings ([@bib1760]). Conversely, actual cases of PD may be missed, particularly in older age groups, where slowness and tremor may be discounted as 'normal' or misdiagnosed as one of several other common disorders affecting this age group (for example, arthritis, stroke, dementia). A further difficulty is presented by persons with both parkinsonism and dementia, who may be classified as either primary disorder in different epidemiologic surveys. The common use of neuroleptics in institutionalized elderly, especially those with cognitive impairment, can further confound diagnosis in this age group.

Postmortem validation of clinical diagnosis, although ideal, is rarely available in a population‐based setting. First, because survival with PD typically involves many years or even decades, very long follow‐up is necessary. In addition, clinical diagnostic criteria do not perfectly predict 'classic' postmortem features of PD. Error rates of more than 20% were seen in one clinicopathological series by [@bib1150]. The same authors later suggested that the use of standard clinical criteria (e.g. the UK PD brain bank criteria) improved accuracy of a clinical diagnosis in 100 patients ([@bib1160]) in which 90 were shown to have idiopathic PD at postmortem and 10 had other parkinsonian syndromes. In a report published the following year (*n* = 143), [@bib1170] estimated that the positive predictive value of the clinical diagnosis for the whole group was 85.3%, with 122 cases correctly clinically diagnosed, 98.6% (72 out of 73) for idiopathic PD, and 71.4% (50 out of 70) for other parkinsonian syndromes. However, since autopsy is most likely performed when the clinical diagnosis is not certain, misclassification may be overestimated in published series ([@bib1520]). Nonetheless, in the few settings where postmortem validation of PD is possible, valuable insights can result ([@bib2120]).

The uncertainty of clinical diagnosis can be an important consideration in the design and critical analysis of epidemiologic studies of PD. Inclusion of those without disease and exclusion of those with disease can produce under‐ or overestimates of the distribution of PD. In either case‐control studies or family studies, including case subjects who do not actually have PD can obscure a causative association or even result in associations with factors determining a different disorder. In families, the mode of inheritance of a genetic defect can also be misinterpreted.

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are imaging techniques that detect and display the distribution of radiolabeled tracers within the body. Patients with PD show reduced tracer accumulation in the striatum contralateral to the affected limbs using markers of the presynaptic dopaminergic system in the very early stages of the disease ([@bib1550], [@bib2540], [@bib0130]). Others have suggested that ultrasound may be a useful way of identifying nigral injury in PD ([@bib0160]). Although these approaches are promising, their abilities to distinguish normal from abnormal and to distinguish PD from other forms of parkinsonism have not yet been developed to the extent that any of these techniques can be used outside the research setting. In epidemiologic research, broad application of these techniques remains difficult, as they are not widely available. However, combining these tools with other, more easily characterized, potential biomarkers, such as olfactory testing, may be useful in prospective studies to identify those 'at risk' for developing parkinsonism, to identify those persons appropriate for interventions to protect against PD and to provide better methods for case definition in studies of genetic and environmental risk factors, where incorrect classification of cases and controls could significantly alter results ([@bib2250], [@bib2290]).

Investigations of new cases of PD present additional uncertainties, because the definition of a new case is particularly problematic. Onset of the motor features of PD is insidious. It is commonly held that at least 50% of substantia nigra pars compacta cells are damaged before the symptoms of PD prompt medical attention ([@bib0170]). It has long been observed in autopsy series that the pathologic changes of PD can be identified in the brains of persons who were not diagnosed during life; these 'incidental Lewy body' cases increase with increasing age of the population surveyed, and may represent clinically unrecognized PD ([@bib0880]). More recently, improved neuropathological methods led to the proposal that neuropathologic injury in PD begins in lower brainstem and olfactory nuclei, and progresses through predictable stages over time, involving the substantia nigra and producing classical parkinsonism only relatively late, at stage 4 ([@bib0280], [@bib0300]). Lewy neurite pathology can also be seen in autonomic ganglia outside the central nervous system, leading to the further hypothesis that PD may begin outside the central nervous system, well before the classic signs of parkinsonism develop ([@bib0290]). If this is correct, the true onset of the disease process may begin long before the neurological syndrome is diagnosed. This research hypothesis merits further investigation. To be effective, studies of risk or protective factors, as well as investigations of preventive therapies, may need to target time periods decades before the onset of disease.

6.2. Demographics {#s0040}
=================

6.2.1. Incidence {#s0050}
----------------

*Incidence*, the number of new cases of a disorder diagnosed during a specific time interval within a defined population, provides the most complete description of the number of cases of disease, as this measurement is least affected by factors influencing survival. This is particularly important for a slowly progressive disorder such as PD. However, as discussed above, because the time of onset of PD is not easily determined, incidence can vary depending on the definition of disease, as well as by factors such as method of ascertainment and access to health care. Studies using more intensive ascertainment methods, such as in‐person screening, may find higher rates ([@bib0570]). Crude estimates of incidence can also vary due to the age and gender distribution of the population studied, and crude rates must be compared with this in mind. For example, reported incidence of PD varies fourfold, from 4.5 to 19 per 100 000 population per year when the entire age spectrum of the population is considered ([@bib2090], [@bib0980], [@bib0110], [@bib0910], [@bib1650], [@bib2310], [@bib0720], [@bib1350], [@bib0250], [@bib1340], [@bib1490], [@bib2470], [@bib2490]). However, when studies using similar methods are compared, and rates are adjusted to a reference population, this range is markedly reduced (11.0--13.9/100 000 population per year; [@bib2490]).

Age is a key determinant of PD incidence. In all populations studied, PD is very rare before age 50 ([@bib1360], [@bib0320], [@bib2090], [@bib0110], [@bib0910], [@bib2530], [@bib2380], [@bib0980], [@bib1650], [@bib1710], [@bib1560], [@bib2490], [@bib1300]). PD incidence increases steadily in the sixth through the eighth decades in most populations, but a decrease in late life is seen in some studies. Whether this apparent decline in PD incidence is the result of methodologic challenges, such as the greater difficulty identifying and diagnosing PD in the very old ([@bib0260]), rather than an actual decline in disease frequency, is not certain. If the decline is real, a biological 'window of vulnerability' for PD may exist. Investigation of the determinants of this could provide important insights into the causes of PD.

PD incidence is also higher in men than in women in most populations studied, although gender‐specific differences show more variability worldwide than do differences associated with increasing age. In a large study in northern California, PD incidence in men was 91% higher than for women (19/100000 for men versus 9.9/100000 for women, age‐adjusted; [@bib2490]).

Whether PD incidence varies by racial or ethnic group has been addressed in only a few studies. In a northern California population, estimated PD incidence, adjusted for age and gender to a comparison population, was highest in Hispanics (16.6/100 000), then non‐Hispanic whites (13.2/100 000), then Asians (11.3/100 000) and lowest in blacks (10.2/100 000; [@bib2490]). When rates in other incidence studies were adjusted to the same comparison population, PD incidence in northern Manhattan was higher in blacks (18/100 000) than in whites (12.9/100 000) or 'other' (11.8/100 000), and PD incidence in men of Japanese and Okinawan descent in Honolulu was 13.1/100 000 ([@bib1650], [@bib1710]). Whether these variations within and across populations reflect real differences, or simply poor precision, resulting from small numbers of PD cases, will only be answered by additional race‐ and ethnicity‐specific studies.

Has PD incidence changed over time? Periodic fluctuation in incidence could result from any episodic exposure, such as an infectious process. A steady increase over the past several decades could implicate exposures increasingly present, such as those due to industrialization or lifestyle practices. Conversely, if PD incidence has remained stable over time, recent environmental factors are unlikely to be important causes of PD. Only two reports have addressed this possibility, with differing results. Reviews of the Mayo Clinic database from Olmsted County, Minnesota, found no change in age‐specific PD incidence between 1935 and 1990 ([@bib2040], [@bib2080]). One limitation to this work is the small population size. Only 154 PD cases were incident in 15 years, resulting in poor precision of these estimates. In contrast, in southwestern Finland, based on a larger number of cases, estimated incidence of PD was increased in men, particularly those aged 60 and older, in 1992 as compared to 1971 ([@bib1340]). Although it is possible that these differences may reflect temporal changes in environmental exposures in Finland, but not in Minnesota, this cannot be determined from the published studies.

6.2.2. Prevalence {#s0060}
-----------------

Because PD is relatively uncommon and associated with a long survival, estimates of prevalence are more easily obtained than estimates of incidence. PD prevalence is most commonly estimated through national or local reporting systems. In locations where health care is universally available, such methods provide a good estimate of correctly diagnosed cases, but exclude persons who have not sought medical care. Misclassification is dependent on the methods used to define cases, with those diagnosed by experts being likely the best estimates of PD in the population. Estimates of prevalence based on populations identified by other methods (such as participants in a hospital clinic) do not accurately reflect the general population of an area, since cultural, economic or other factors may influence case selection.

Ideally, both incidence and prevalence are determined by screening all members of entire populations defined by specific geographic or political boundaries. Door‐to‐door surveys of all households in an area, followed up by examination of individuals suspected of having parkinsonism based on the screen, is the generally the best measure of true prevalence. If cooperation is good, a door‐to‐door survey is the most likely means of identifying all cases of PD in a community. Typical community‐based and door‐to‐door prevalence studies utilize health professionals or, more often, trained survey assistants who screen the population using a set of questions designed to identify all individuals who may have the disease ([@bib0060]), even those who have not received medical attention ([@bib2370], [@bib1770], [@bib0650], [@bib0900]). After the initial screening process, individuals suspected of having the disease are asked to have a careful evaluation performed by a neurologist and possibly ancillary diagnostic tests.

The estimated PD prevalence derived from medical care reporting systems in North America and Europe find rates between 100 and 200 cases/100 000 population, although rates in developing countries are reported to be as little as one‐tenth of these rates ([@bib1360], [@bib0320], [@bib1210], [@bib1600], [@bib1260], [@bib1270], [@bib2090], [@bib1810], [@bib0980], [@bib2320], [@bib0110], [@bib0380], [@bib1760], [@bib2240], [@bib1820], [@bib0910], [@bib2530], [@bib0350], [@bib1640], [@bib1650], [@bib2380], [@bib1710], [@bib1110]). [Table 6.2](#t0020){ref-type="table"} shows examples of crude estimated prevalence from door‐to‐door studies ([@bib1460], [@bib2160], [@bib2170], [@bib0200], [@bib0040], [@bib1730], [@bib2510]). Recently, estimates as high as 780/100 000 have been reported in Sydney, Australia ([@bib0400]).Table 6.2Parkinson\'s disease prevalence rates from selected door‐to‐door surveysLocation of surveyAge groups screenedCrude prevalence/ 100 000 personsChinese cities ([@bib1460])\> 50 years44.0Igbo‐ora, Nigeria ([@bib2170])\> 39 years58.6Kin‐Hu, Kinmen, Taiwan, ROC ([@bib2510])\> 50 years170.0Sicily, Italy ([@bib1730])\> 12 years257.2Vejer de la Frontera, Cadiz, Spain ([@bib0040])All ages270.0Copiah County, Mississippi, USA ([@bib2160])\> 39 years347.0Parsi community, Bombay, India ([@bib0200])All ages328.3Bankstown, Sydney, Australia ([@bib0400])≥ 55 years780.0[^1]

Comparison of prevalence studies worldwide suggests that PD may be more common in the developed world. Because there are many methodological differences among studies, as well as differences in culture and health care among countries, this observation must be viewed with caution. Importantly, crude prevalence rates cannot be compared directly, since different age groups were surveyed, and the age distribution in the underlying populations differ. Longevity increases the number of PD cases one can expect in a population. While age adjustment reduces differences across populations, the range of estimated PD prevalence remains broad. Comparisons of prevalence for PD from different populations can also reflect the relationship between prevalence and methodology used. For example, apparent age‐specific prevalence differences among studies may actually be quite similar when data are re‐evaluated according to the same diagnostic criteria ([@bib0070]).

In one study, PD prevalence has been estimated at two time points. In southwestern Finland, PD prevalence appears to be increasing in men and in rural areas in 1992 as compared to 1971 ([@bib1340]). Because ascertainment methods were similar at both time points, this may reflect a true difference in prevalence in this region, possibly the result of changes in exposure to risk factors. Lending more credence to this is the observation that similar changes in incidence were observed, making it less likely that the prevalence changes are due to improved survival of persons with PD in 1992.

### 6.2.2.1. Age {#s0070}

Although PD is rare before age 40, after age 50 the prevalence rises almost exponentially ([@bib1360], [@bib0320], [@bib1210], [@bib1600], [@bib1260], [@bib1270], [@bib2090], [@bib0980], [@bib1460], [@bib2160], [@bib2170], [@bib2320], [@bib0110], [@bib1760], [@bib2240], [@bib0040], [@bib1640], [@bib1650], [@bib1730], [@bib2380], [@bib2510], [@bib1710]). By the eighth decade, estimated prevalence in European and North American populations is between 1000 and 3000 cases per 100 000 population. Although differences in the age distributions in these populations, diagnostic criteria, ascertainment methods, access to health care or disease survival rates may explain much of this variation, international variation in PD frequency is seen even after adjusting for many of these inconsistencies ([@bib2610]). Risk factors, which may vary geographically, include both genetic differences in disease susceptibility and exposure to causative and protective environmental factors. Although PD is intimately related to aging, it has been well documented that its underlying process is distinct from natural aging ([@bib1670], [@bib0760], [@bib0880]). An age‐determined process, such as an acquired defect in cellular metabolism, or a process requiring a long period of time to manifest -- as might result from prolonged toxicant exposure or the cumulative effects of many individual injuries to nerve cells -- might cause a similar pattern. It is also possible that both age‐related vulnerability and time‐dependent processes explain the late‐life preponderance of PD.

### 6.2.2.2. Gender {#s0080}

Men are diagnosed with PD about twice as often as women, irrespective of geographic location or race ([@bib2350], [@bib0120]). This pattern is seen in both prevalence and incidence studies. In a meta‐analysis of seven incidence studies, men were found to have a 1.5‐times greater relative risk for PD than women ([@bib2590]).

This increased risk in men may reflect biological differences between men and women, such as the effects of sex hormones or X‐chromosome‐linked susceptibility genes. Alternatively, culturally determined differences in male and female behavior, with associated differences in exposure to risk factors, could explain the pattern. The latter hypothesis is supported by a large Finnish study showing a dramatic increase in the male‐to‐female relative risk from 0.9 in 1971 to 1.9 in 1992 ([@bib1340]). Others have suggested that hormonal differences between men and women explain these differences, although the relationship does not appear to be a simple one (see also [section 6.3.7](#s0330){ref-type="sec"}). Further epidemiologic studies, along with experimental laboratory studies, will be necessary to determine whether men are at greater risk for PD.

### 6.2.2.3. Race {#s0090}

Although there are a surprising number of observations in the literature suggesting whites are at increased risk for PD, it has been thought that lower rates in non‐whites might be related to socioeconomic or cultural differences, leading to ascertainment bias ([@bib1260], [@bib1270], [@bib2350]). Nevertheless, two multiracial population‐based studies estimating the incidence of PD in upper West‐Side Manhattan ([@bib1650]) and in Northern California ([@bib2490]) suggest racial differences in PD incidence. In the Manhattan study, African‐American women had lower rates, but African‐American men had higher rates than whites ([@bib1650]). The Northern California study, a much larger evaluation of PD incidence, showed a lower frequency of PD in both men and women of African or Asian descent than in non‐ Hispanic whites ([@bib2490]). Results remain equivocal in both studies, however, as even in this large study the numbers of non‐whites were low and between‐group confidence intervals for race‐specific PD incidence overlapped.

If there are true differences in PD risk among groups defined by race or ethnicity, this may reflect differences in biologic susceptibility. For example, mutations in the *LRRK2* gene account for about 2% of parkinsonism in northern European populations, but 15--20% in persons of Ashkenazi Jewish and North African origin ([@bib1440], [@bib1850]). Others have suggested that dermal melanin may protect against PD by trapping potential neurotoxins before they reach the brain ([@bib1630]). Because dermal melanin is regularly sloughed with keratinized skin, persons with more dermal melanin may be protected from the passage of toxicant compounds into the central nervous system. Alternatively, differences in non‐genetic risk factors may explain differences among populations. For example, PD prevalence is high in the Inuit population of Greenland ([@bib2550]). This population is at risk for dietary and other exposures to persistent organic pollutants ([@bib0600]), agents suggested to be risk factors for PD.

6.2.3. Mortality {#s0100}
----------------

Studying mortality of PD based on information from death certificates is problematic because PD is a chronic disorder that is not the direct cause of death; thus, the frequency of the disease can be underestimated from such evaluations. Compared to persons of the same age and gender, mortality is increased approximately twofold among individuals with PD ([@bib0620], [@bib1710], [@bib1480], [@bib1740]). An observed north--south gradient of decreasing PD mortality ([@bib1470]), although possibly reflecting true differences in regional mortality, could also be an artifact of differential access to medical care or death certificate completion inconsistencies among physicians ([@bib1990]).

Mortality in a clinical trial population may be affected by the influence of the health benefit obtained from participating in the study. After a 13‐year follow‐up, results from the DATATOP cohort study show that the mortality rate was similar to that of the general population and that PD did not affect survival differently across gender or age groups in a selected group of otherwise healthy clinical trial participants ([@bib1570]). In other clinical trial populations, mortality has been higher than expected, however ([@bib1030], [@bib1420], [@bib0740]). Among participants in the DATATOP study, severity, rate of worsening of parkinsonism and response to levodopa are related to survival ([@bib1580]), suggesting that differences in these factors among studies may also account for the observed differences in PD‐related mortality among these studies.

6.3. Risk factors for Parkinson\'s disease {#s0110}
==========================================

6.3.1. Introduction to epidemiologic clues {#s0120}
------------------------------------------

The demographic studies reviewed in the previous section may provide clues to the causes of PD ([Table 6.3](#t0030){ref-type="table"} ). Demographic differences in the frequency of PD, particularly differences in PD incidence, may be the result of ascertainment bias. Alternatively, differences in risk factors for PD among different demographic groups may explain these patterns. Some of these possibilities have been discussed above. Disease clusters, representing more than the expected number of new cases of PD at a certain time and/or in a certain place, are another type of pattern that may suggest a shared cause of disease and provide clues to the underlying etiology of all cases. An example is the cluster of parkinsonism in narcotics addicts caused by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) exposure ([@bib1390]) ([Fig. 6.1](#f0010){ref-type="fig"} ). MPTP induces parkinsonism that is similar to PD, with key symptoms that improve with levodopa treatment and a similar side‐effect profile. Differences include the more rapid onset of symptoms in MPTP‐induced parkinsonism than in PD, and possibly some differences in neuropathologic features as well. Although MPTP injection is clearly not a cause of most PD, investigation of this cluster provided an important animal model. Investigation of the mechanism of MPTP toxicity led to the hypothesis that toxicants may cause PD, and has focused interest on compounds with structural or functional similarities ([Fig. 6.2](#f0020){ref-type="fig"} ). Other proposed clusters, such as the syndrome of motor neuron disease--parkinsonism--dementia in certain areas of the Western Pacific ([@bib2260]) or several clusters in Canada ([@bib1330]) have yet to reveal specific etiologic factors.Table 6.3Factors associated with the risk of Parkinson\'s disease in one or more studies**Factors directly associated**Increasing ageMale genderWhite raceDrinking well waterDiet: animal fat, milk, ironObesityHysterectomy and/or supplemental estrogenMidlife constipationRapid‐eye movement sleep disorderPhysical and emotional stressFamily history of Parkinson\'s diseaseRural residencePesticidesFarmingTeaching/health care workMetals**Factors inversely associated**Smoking/tobaccoCaffeine intakeNon‐steroidal anti‐inflammatory drug useAlcoholGreater physical activityFig.6.11‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridin (MPTP) and structurally related compounds. MPP, 1‐methyl‐4‐phenylpyridinium.Fig. 6.2Epidemiologic clues and mechanisms of neuronal injury. TIQs, tetrahydroisoquinolines; MPP^+^, 1‐methyl‐4‐phenylpyridinium ion; LPS, lipopolysaccharide.

Familial clusters are generally interpreted to indicate a genetic cause for disease, but certain patterns within families, such as temporal clustering of disease, may be more suggestive of shared environmental risks. A number of case‐control studies have found increased PD risk if a first‐degree relative has PD ([@bib2230], [@bib1700], [@bib1920], [@bib0220], [@bib0580], [@bib1530]). Because persons with disease may be more aware of disease in relatives, these studies in part may reflect reporting bias. [@bib0680] showed evidence for family information bias whereby cases with PD are more likely to report a relative with PD than are control subjects, increasing the risk estimate by 133%. Studies in twins do not support a genetic cause for typical age at PD onset, although genetic factors appear to be increased in those with younger age at onset ([@bib0660], [@bib1590], [@bib1620], [@bib2500], [@bib2340], [@bib2580]).

Many proposed risks for PD will be reviewed here.

6.3.2. Single genes causing parkinsonism {#s0130}
----------------------------------------

Genetic defects responsible for parkinsonism have been identified in some families ([@bib0220], [@bib1930], [@bib1940], [@bib0990], [@bib1280], [@bib1880], [@bib2620]). In many of these cases, the clinical features resemble typical PD. However, within affected families there are often clinical features that are unusual for PD. At present, mutations in at least five genes have been firmly associated with parkinsonism: (1) α‐synuclein (*SNCA* or *PARK1*; [@bib1940]); (2) parkin (*PRKN* or *PARK2*; [@bib1280]); (3) DJ‐1 (*DJ1* or *PARK7*; [@bib0230]); (4) PTEN‐induced putative kinase I (*PINK1* or *PARK6*; [@bib1940]); and (5) leucine‐rich repeat kinase 2 or dardarin (*LRRK2* or *PARK8*; [@bib1880], [@bib2620]) ([Table 6.4](#t0040){ref-type="table"} ). *PINK1* homozygous mutations have been reported to be an important cause of disease among Italian sporadic patients with early‐onset parkinsonism, whereas the role of single heterozygous mutations is less clear ([@bib0240]). The *LRRK2* G2019S mutation is the most common pathogenic mutation linked to parkinsonism, accounting for 1--2% of cases, including cases of not only younger but also older age at disease onset ([@bib1250]). Other candidate PD loci have been proposed, including putative disease‐causing mutations in the ubiquitin carboxy‐terminal hydrolase L1 (*UCHL1*) ([@bib1430]) and in a nuclear receptor of subfamily 4 (*NR4A2* or *NURRI*) ([@bib1410]). These candidates do not map to known PD linkage regions, but polymorphisms in both genes have been associated with PD in some case‐control studies (as reviewed by [@bib0180]). The *GSK3B* polymorphism has been reported to alter transcription and splicing and interact with tau haplotypes to modify PD risk ([@bib1370]).Table 6.4Genes causing parkinsonismLocus/geneMap positionCharacteristics**Dominantly inherited***PARK1* (α‐synuclein)4q21--22Rare point mutations, duplication/triplication of normal geneAtypical features, young onset*PARK8* (*LRRK2*/dardarin)12p11.2‐q13.1Sporadic and familial, heterogeneous signs and pathologyOld and young onsetRecessively inherited*PARK2* (parkin)6q25--27Many mutations, atypical, most onset \< 30 years of age*PARK6* (*PINK1*)1p35--36Two mutations in three consanguineous families*PARK7* (DJ‐1)1p36Point mutation, deletion, few families, atypicalUncertain inheritance*PARK5* (*UCHL1*)4p14[^2]

From an epidemiologic perspective, the monogenic causes of PD appear to constitute a proportion of cases worldwide. However, investigation of the protein products of these genes can further our understanding of the process of nerve cell death in parkinsonism. Investigation of these forms has emphasized the role of key proteins (like α‐synuclein) and molecular pathways leading to neurodegeneration. Intriguingly, mitochondrial mechanisms, oxidative stress and protein clearance appear to be pathogenic in animal models derived both from toxicant and genetic forms of parkinsonism ([@bib0550], [@bib0610]).

6.3.3. Proposed environmental risk factors for Parkinson\'s disease {#s0140}
-------------------------------------------------------------------

Risk factor investigation in PD is challenging, as the time of life most important to investigate is not known. It is likely that years, and possibly even decades, pass between the time of risk factor exposure and the clinical onset of parkinsonism. Case‐control studies are an efficient way to study proposed disease risk factors, particularly in relatively uncommon disorders, such as PD. Potential limitations to this design include biased recall, the lack of validation of exposure and, in prevalent studies, survivor bias. Prospective cohort studies, assessing risk factors in advance of disease, avoid many of the biases of case‐control studies, but risk factor investigation is limited to those selected for study and diagnostic accuracy may be less certain.

### 6.3.3.1. Rural living, farming, well water {#s0150}

Numerous studies worldwide have identified rural living, farming, gardening and drinking well water as risk factors for PD ([@bib2220], [@bib0340], [@bib1120], [@bib1700], [@bib0790], [@bib0930], [@bib1540], [@bib2630], [@bib1300]), but the results are somewhat inconsistent because of differences in the way the studies assessed the effects of rural living. Overall, risk of PD appears to be increased in rural dwellers -- especially in the USA. Meta‐analysis results ([@bib2000]) also support that risk factors include farm living and use of well water and pesticides. Although the specific associations are varied, the consistency of the general finding is remarkable.

### 6.3.3.2. Pesticides {#s0160}

Pesticide exposure is associated with an increased risk of PD in many reports. A meta‐analysis of 19 published studies found a combined odds ratio (OR) of 1.94 (95% confidence interval (CI) 1.49--2.53) for pesticide exposure ([@bib2000]). However, the category of pesticides is very broad, and includes chemicals with many different mechanisms of action. Only a few studies have identified specific compounds or compound classes, including herbicides, insecticides, alkylated phosphates, organochlorines, wood preservatives, dieldrin and paraquat ([@bib0810], [@bib1300]).

Most of these studies have been limited by very broad measures of exposure. In many studies, the proportion of exposed persons was low, little was known about specific exposures and validation of exposure was not possible.

Gene--environment interaction may also be important, and those with impaired pesticide metabolism may be most vulnerable. A recent report ([@bib0700]) indicates an increased risk of PD with pesticide exposure in normal metabolizers, and about twofold increase in risk with pesticide exposure for CYP2D6 poor metabolizers, and no effect of the metabolizing status on risk for PD without pesticide exposure.

### 6.3.3.3. Metals {#s0170}

Iron has been shown to cause a higher susceptibility to oxidative stress in two ways. By depleting stores of glutathione, iron may have a role in the progression of parkinsonism associated with exposure to other chemicals that are metabolized to free radicals and/or contribute to the adverse effects of oxidative stress ([@bib1240]). Also, since iron has a strong catalytic power to generate highly reactive hydroxyl radicals from iron (II) and hydrogen peroxide, increased levels of iron in the brain can increase oxidative stress (Fenton reaction). Excessive iron accumulation in the brain is also a potential risk for neuronal damage, which may be promoted by other triggering factors ([@bib1380]). A combined high dietary intake of iron and manganese may increase the risk of developing PD ([@bib1970]). Dietary intake of manganese alone does not seem to have toxic effects, except among individuals with liver failure ([@bib1000]). Although dietary intake is the main source of non‐occupational exposure to manganese, occupational exposure seems to be a more influential PD risk factor. Case‐control studies suggest that occupational exposure to metals ([@bib0940], [@bib2020]) may be at increased risk of PD, although cohort studies have not replicated this ([@bib0840], [@bib0820]).

### 6.3.3.4. Polychlorinated biphenyls (PCBs) {#s0180}

PCBs are among the group of compounds classified as persistent environmental pollutants. In the USA, industrial use was common until 1977. Today, PCBs continue to cycle in the environment. Common sources of human exposure are fish and marine mammals, meat and dairy products. In laboratory studies, PCBs have been shown to reduce dopamine levels in the brain areas affected in PD ([@bib2200], [@bib0500]). The association between PCBs and PD has been studied in a blinded comparison of postmortem determinations of caudate PCB concentrations in PD patients and controls ([@bib0530]). PD brains had significantly higher levels of PCB congener 153, and several other congeners tended to be higher in PD caudate. Also increased in PD brains were the organochlorine pesticide dieldrin and the dichloro‐diphenyl‐trichloroethane (DDT) metabolite 1,1‐dichloro‐2,2‐bis(4‐chlorophenyl)ethene (DDE). In a previous investigation, frontal cortex of PD patients and controls did not show differences in PCB or organochlorine levels. This regional specificity lends indirect support to an association between PCBs and PD.

### 6.3.3.5. Occupation {#s0190}

Given the increasing evidence that environmental factors play a role in PD, there has been an increasing effort to identify occupational risk factors, but to date few have been identified. A higher frequency of PD has been reported among teachers and health care workers ([@bib2460]). These findings were replicated in a case‐control study in twin pairs discordant for PD ([@bib2400]), and in very large occupational mortality studies in the USA ([@bib2180]) and the UK ([@bib0510]). It has been suggested that an infectious etiology could explain the increased risk in these occupational groups. Alternatively, these associations could be related to some other unrecognized occupation‐associated risk factor, to premorbid personality characteristics predisposing to certain occupations ([@bib1690]) or to issues of study design, such as ascertainment bias or confounding by age or other factors. A higher frequency of PD has also been reported in carpenters and cleaners ([@bib0730]) and in workers chronically exposed to metals ([@bib0940]). Welding has been proposed as a risk factor ([@bib2020]), but this finding is controversial ([@bib0840]), with recent results from a nationwide linkage study indicating no support for an association between welding and PD, or any other specific basal ganglia and movement disorders ([@bib0820]). Overall, results from the available studies are inconclusive, reported findings need confirmation and not all occupations have been evaluated. Differences within even one type of occupation make occupation groups heterogeneous and comparisons difficult.

Querying occupation in such a way that it triggers exposure‐specific questions as described by [@bib2280] may be more useful, but the potential misclassification of specific exposures will be appreciable and tend to bias effect measures toward the null -- occupational exposures in community‐based studies are rare, which compounds the problem ([@bib2430]). Ideally, in addition to asking about occupation and exposure, there should be a quantitative measure in exposure‐response analyses -- for most chronic diseases the exposure measure of choice is the level of exposure multiplied by the duration of exposure. The use of a single variable for primary lifetime occupation is problematic. Undoubtedly, most people work at a number of different jobs throughout their lives, and important associations may be missed or misclassified. A lifelong, job task‐specific occupational history has the potential to provide more complete information, and direct interviews may improve historical accuracy. Studies within specific at‐risk groups such as occupational cohorts can be important in clarifying whether there is a relationship between occupation and PD.

6.3.4. Diet, obesity, physical activity {#s0200}
---------------------------------------

### 6.3.4.1. Diet {#s0210}

Diet is a very difficult exposure to measure both because of its complexity and the fact that most individuals have qualitatively relatively similar diets ([@bib2570]). Despite these challenges, several dietary factors have been associated with PD.

Excess intake of dairy products has been associated with increased risk of PD in two large prospective cohorts ([@bib0430], [@bib1900]). In a study of health professionals, whether the effect was due to calcium or milk could not be determined. Moreover, the risk was most marked in men, and not clearly observed in women. In the second study, PD incidence was more than twice as high in men drinking more than 16 ounces (approximately 450 grams) daily in midlife, compared to those who consumed no milk. This effect was independent of calcium. No women were included in this cohort. The reason for this association is unclear. One explanation is that milk may be a vehicle for potential neurotoxicants such as organochlorine pesticides or tetrahydroisoquinolines.

Other studies suggested different dietary risk factors for PD. PD risk was mildly raised in association with high dietary iron intake, but the risk markedly increased with high intake of both iron and manganese ([@bib1970]). Another study ([@bib2150]) indicated increased risk with high vitamin C, carotenoids and sweet food, including fruit intake, but the number of cases studied was small (*n* = 57). Among those with PD, homocysteinemia has been indicated as a potentially reversible risk factor for depression or cognitive decline ([@bib1840]).

Studies of dietary antioxidant intake have been largely inconclusive. It is biologically plausible that dietary antioxidants may protect against nigral damage, analogous to their potential role in preventing heart disease and stroke ([@bib2070], [@bib1290], [@bib1320], [@bib0860]). One prospective cohort study of 41 836 women indicated a significant protective effect seen for both vitamin C and manganese consumption; however, vitamin A intake was associated with an increased risk of PD ([@bib0370]). A sibpair study ([@bib1510]) reported a 3.2‐year older mean age at onset for affected siblings who reported taking multivitamins. Protective effects were proposed for B vitamins and folate, because of their shared pathways with homocysteine and ability to lessen oxidative stress ([@bib0640]). Comparison of two large prospective cohorts ([@bib0450]) with 415 cases indicated PD risks did not differ in relation to dietary intakes of B vitamins and folate (relative risk 1.0 (95% CI 0.7--1.5) comparing the lowest to the highest intake quintile in men and 1.3 (95% CI 0.8--2.3) in women).

Dietary insufficiency has also been proposed as a risk factor for the development of PD, although evidence for this is indirect. In a 20--30‐year follow‐up of a cohort of ex‐Far‐East prisoners of war, who experienced severe dietary insufficiency between 1942 and 1945 ([@bib0890]), 24 PD cases were identified out of 4684 subjects, producing a crude prevalence rate of 512 per 100 000. This is particularly high considering the relatively young age of the cohort and the observation that 15 cases (63%) had disease onset under the age of 50 years. Emotional and physical stress has also been implicated in increased frequencies of PD in another study of prisoners of war ([@bib1870]), although a relationship to dietary insufficiency could not be determined.

Certain exotic dietary exposures have been proposed to cause atypical forms of parkinsonism, including ingestion of indigenous species from Guam ([@bib2260], [@bib1750]), or the British West Indies ([@bib0390]), although these reports are controversial.

### 6.3.4.2. Obesity {#s0220}

Conversely, oxidative stress may be increased by lipid consumption and higher caloric intake, and eating foods high in animal fat has been associated with increased risk of PD in several studies ([@bib1300]). The link between measures of body composition and obesity and risk of PD is unclear. A large study in Japanese‐American men in Hawaii observed higher prevalence of PD with higher triceps skinfold thickness, subscapular skinfold thickness and body mass index ([@bib0020]). A similar analysis in the Nurses\' Health and the Health Professionals\' study did not find an association between body mass index and risk of PD but, among never smokers, both waist circumference and waist--hip ratio showed significantly positive associations with PD risk as compared to smokers ([@bib0460]).

### 6.3.4.3. Physical activity {#s0230}

Animal models have also been used to study the role of physical activity in PD. Results of studies of forced limb use in 6‐hydroxydopamine‐injected rats ([@bib0520]) suggest that preinjury forced limb use can prevent the behavioral and neurochemical deficits. In treadmill tests of MPTP‐injected rats ([@bib2440]), exercise following the nigrostriatal damage ameliorated related motor symptoms and neurochemical deficits.

Physical activity in epidemiological studies includes cohort results by [@bib0470] that show either that higher levels of physical activity may lower the risk of PD in men, or that men predisposed to PD tend to avoid strenuous activity in their early adult years. A significantly lower level of physical activity was present before diagnosis (men, 12 years prior; women, 2--4 years prior), and there was a sustained decrease in physical activity after diagnosis. Case‐control studies, however, have shown inconsistent results. In one Chinese hospital‐based study investigating risk factors for classic‐onset versus young‐onset PD, the duration of exercise was substantially longer in the young‐onset group than in controls or in the classic‐onset PD group ([@bib2450]). In another small study assessing the lifetime physical activity via sports/leisure activity and participation using visual analog scales, there was no difference in lifetime physical activity between cases and controls; however, there was a greater decline in activity after age 50 years in those with PD ([@bib0800]). In a nested case‐control study of male Harvard students, moderate physical activity was associated with a lower risk of PD, but this association was not seen at higher levels of physical activity ([@bib2140]).

6.3.5. Inflammation, infection, head trauma, non‐steroidal anti‐inflammatory drugs (NSAIDs) {#s0240}
-------------------------------------------------------------------------------------------

### 6.3.5.1. Inflammation {#s0250}

Several lines of evidence support the idea that inflammation is involved in the pathogenesis of PD ([@bib1100]). Postmortem analyses showed gliosis and clustering of microglial cells around nerve cells in 3 subjects who had presented with MPTP‐induced parkinsonism 3--16 years earlier ([@bib1400]). In cell culture experiments injection of lipopolysaccharides (LPS), which activate glia, killed dopaminergic neurons in mixed neuron--glia but not in pure neuron cultures ([@bib0330]). In an animal model, a single intranigral injection of LPS damaged dopaminergic but not serotonergic or GABAergic neurons ([@bib1090], [@bib0870]). Application of dexamethasone before LPS injection prevented the loss of catecholaminergic content, tyrosine hydroxylase activity and immunostaining, and the microglia‐macrophage activation seen previously ([@bib0360]).

Human studies revealed elevated cytokine levels, which induce glia activation, in the brain and cerebrospinal fluid of PD patients compared to controls ([@bib1780]). Additionally, increased expression of tumor necrosis factor‐α, interleukin‐β and interferon‐γ was observed in the substantia nigra of PD patients ([@bib0210], [@bib1180]). In recent epidemiologic studies, intake of NSAIDs was inversely associated with PD risk ([@bib0440]); more detailed analysis indicated that the association was significant for ibuprofen but not other NSAIDs ([@bib0480]). Higher levels of uric acid, a potent antioxidant, during midlife were associated with a 40% reduced risk of PD in one prospective cohort ([@bib0540]). This observation was recently replicated in a nested case‐control study in the health professional prospective cohort study ([@bib9010], unpublished; see [@bib9010] for abstract). However, uric acid levels can be increased by several agents inversely associated with PD, including alcohol, caffeine and aspirin, as well as by levodopa. Further studies are needed to determine whether this is a primary or secondary association.

### 6.3.5.2. Infections {#s0260}

The observation that encephalitis lethargica often resulted in parkinsonism during the influenza pandemic of the early 1900s suggested a possible infectious etiology for PD. Since that time, however, clinical and neuropathological criteria have clearly differentiated postencephalitic parkinsonism from typical idiopathic PD. Although subsequent studies have been unable to identify an infectious agent in PD ([@bib1610], [@bib2520]), a number of studies have continued to suggest that infection may play a role in idiopathic PD. As described previously, increased PD frequency in health care workers and teachers has been linked to infection ([@bib2180]). One study observed elevated coronavirus antibody levels in the cerebrospinal fluid of PD patients, supporting a possible link of PD with coronavirus infections ([@bib0750]), a common cause of respiratory infections. Another study noticed reduced risk for PD associated with most viral childhood infections, especially measles ([@bib2130]); both studies await replication. The soil pathogen *Nocardia asteroides* causes a levodopa‐responsive movement disorder and nigral degeneration in mice ([@bib1310]), but a serologic case‐control study did not support its role in human PD ([@bib1140]).

### 6.3.5.3. Head trauma {#s0270}

Previous head trauma has been associated with PD in numerous case‐control studies ([@bib0190], [@bib2360], [@bib2270], [@bib2230], [@bib2480], [@bib0270]). Head injury can trigger an inflammatory cascade, or conceivably disrupt the blood--brain barrier, increasing risk of exposure to toxicants or infectious agents. In a sibpair study ([@bib1510]) and a study of twin pairs concordant for PD ([@bib0920]), the sibling with younger‐onset PD was more likely to have sustained a head injury. In twins discordant for PD, a previous head injury with amnesia or loss of consciousness was associated with a nearly fourfold increased risk of PD. Significant head injury is rare, however, and there may be a latency up to 30 years between injury and PD diagnosis, minimizing the chance that disease‐related disability caused the injury ([@bib0710], [@bib2210], [@bib2410]). Severity of head injury is likely to be important and there may be a dose effect; there is no association with PD and mild head injury without loss of consciousness. Nevertheless, medical record validation suggests that this is a real association, not explained by recall bias.

### 6.3.5.4. Non‐steroidal anti‐inflammatory drugs {#s0280}

Inflammatory mechanisms appear to contribute to neurodegeneration in PD, and animal studies suggest that NSAIDs have neuroprotective properties ([@bib1660]) by reducing general inflammation. Studies of Alzheimer\'s disease have shown that the regular use of NSAIDs may reduce the risk of Alzheimer\'s in humans ([@bib0310], [@bib1190], [@bib1660]). The similarities in the pathogenetic background of PD and Alzheimer\'s disease and animal data suggesting that anti‐inflammatory drugs may protect against PD ([@bib0780]) have encouraged investigation of the association between NSAID use and PD risk in humans. An inverse association of NSAID use with risk of PD has been observed in two prospective studies for non‐aspirin NSAIDs, as well as for aspirin ([@bib0030], [@bib0440]). Interestingly, in a cross‐sectional study of 1258 PD cases and 6638 controls from the General Practice Research Database, this inverse association was again observed for men, but not women, in whom non‐aspirin NSAID use was associated with a higher risk of PD ([@bib1080]). Whether this reflects a characteristic of the study population or method, or a true gender difference in risk, will require studies in other populations.

6.3.6. Smoking, caffeine, alcohol {#s0290}
---------------------------------

Although there are a number of health risks associated with smoking tobacco and drinking alcohol, cigarette, coffee and alcohol intakes are all inversely associated with risk for developing PD, suggesting they may be neuroprotective agents.

### 6.3.6.1. Smoking {#s0300}

Not smoking cigarettes is the most consistently observed risk factor for PD. An inverse association between cigarette smoking and PD has been observed in studies spanning more than 30 years, involving diverse populations and including several large prospective investigations ([@bib0630], [@bib0950], [@bib0140], [@bib2560]). A meta‐analysis ([@bib1040]) indicated a 40% reduced risk of PD in smokers. Three basic categories of smoking were evaluated: ever smoking, past smoking and current smoking behavior. Long duration (highest pack/year) correlated with dose, and smoking more than 5 years prior to PD onset was not protective; recent smoking appeared more protective. Other research suggests cigarette smoking, on average, appears to lower the risk of developing PD by about half ([@bib2300]). This inverse association has been reported in nearly every population studied over more than 30 years ([@bib2010]), and a recent study in a population characterized by a high prevalence of occupational pesticide exposure confirms an inverse correlation between cigarette smoking and PD in this potentially 'high‐risk' group as well ([@bib0850]). One report suggests the inverse association of smoking and PD is only present in those with a specific monoamine oxidase‐B allele ([@bib0420]), although this was not replicated ([@bib1050]), and other single observations suggest other interactions of genes and smoking ([@bib2330]).

Non‐smoking behavior in people fated to develop PD may be the result of a lower reward of smoking due to low dopaminergic tone, a genetically conferred decreased propensity to smoke or a premorbid personality ([@bib1690]). Indeed, the personalities of those who have gone on to develop PD have been described as shy, cautious, inflexible, punctual and depressive ([@bib1130]); such persons may be less likely to smoke or drink. In contrast, indirect evidence against this theory derives from a study in twin pairs discordant for PD ([@bib2390]). The twins without PD had smoked more than their brothers. Despite a high correlation for smoking in monozygotic twin pairs, this difference was more marked in the monozygotic pairs, known to be remarkably similar in personality. Similar results have been reported in other studies of twins ([@bib0190]) and siblings ([@bib2190]) discordant for PD.

If there is a biologic effect of smoking, whether this is due to nicotine or a combustion product is not known. Indirect evidence supporting a role for nicotine is provided by the observation that PD was less commonly reported among users of smokeless tobacco in a large prospective cohort ([@bib1830]). Animal studies suggest that nicotine may protect against experimental parkinsonism ([@bib1200], [@bib1980]) ([Table 6.5](#t0050){ref-type="table"} ). Nicotine has been found to protect against transection‐induced and MPTP‐induced dopaminergic neuronal cell loss in rodent substantia nigra ([@bib1200], [@bib1980]). In addition, nicotine has antioxidant properties ([@bib0770]), and increases striatal trophic factors ([@bib1500]). Alternatively, smoking may afford indirect protection by inducing peripheral detoxifying enzymes, or by reducing bioactivation of protoxins. This latter hypothesis is supported by the observation that cigarette smoking reduces monoamine oxidase‐B activity in humans ([@bib0830]).Table 6.5Cigarette smoking and Parkinson\'s disease: some possible biologic mechanismsNicotine• Blocks nigral cell loss (hemitransection, MPTP)• Increases growth factorsCigarette smoke• Reduces MAO‐B activity• Gene--environment interaction of smoking and MAO‐B allele• Complex mixture of combustion products -- other actions?[^3]

Assuming smoking is neuroprotective, one might expect it to delay the onset of PD and improve the course of the disease in people already affected. Neither hypothesis has yet been proven. Two studies compared clinical features and did not find differences between smokers and non‐smokers ([@bib0050], [@bib1890]). Although a study by [@bib1340] reported the mean age at onset in ever‐smoking men was significantly higher than in never‐smoking men, results of four other studies assessing age at onset of PD in relation to smoking status ([@bib0970], [@bib2050], [@bib1720], [@bib1450], [@bib0590]) revealed the same or a younger age of PD onset in smokers. Interestingly, however, in several prospective cohort studies, survival of those persons with PD who continue to smoke cigarettes appears to be similar to, or even somewhat better than, survival of non‐smokers with PD ([@bib0950], [@bib0690], [@bib0490]), in contrast to the typically increased mortality observed in cigarette smokers. This tantalizing preliminary information suggests that some aspect of smoking may not only modify disease risk, but also improve survival once PD is manifest.

### 6.3.6.2. Coffee and caffeine {#s0310}

An inverse association of both coffee and caffeine consumption and PD has been reported in case‐control and cohort studies ([@bib0730], [@bib0140], [@bib2110], [@bib0080], [@bib1860]). For example, a longitudinal study and two case‐control studies of incident PD cases provide provocative evidence that coffee drinking may be inversely associated with PD risk. A longitudinal study of Japanese‐American men indicated greater use of coffee was inversely associated with PD risk in a dose‐dependent fashion ([@bib2110]). A very provocative finding in the same cohort was that greater use of coffee was inversely associated with incidental Lewy bodies at postmortem ([@bib2100]). A similar dose‐dependent inverse association between coffee drinking and PD was observed in two prospective studies ([@bib0140], [@bib2560]), and retrospectively an incident case‐control study in Northern California ([@bib1800]). In each case, the inverse association between PD and coffee drinking continued to be observed in multivariate analyses adjusting for cigarette smoking, alcohol use and other potential confounders. Similar associations had previously been reported in a few case‐control studies of prevalent cases, but these results were inconsistent, and a dose--response gradient was not described ([@bib2350], [@bib0410]).

The effect of coffee appears to differ between men and women, with a direct dose--response association in men (higher consumption associated with lower risk) but a U‐shaped pattern in women, although fewer women have been studied. It has been suggested a potential interaction between hormone exposure, primarily estrogen, and caffeine consumption may mediate PD. In participants of the Cancer Prevention Study II, caffeine intake was associated with a significantly lower mortality of PD in men but not in women ([@bib0100]). In women, the association depended on estrogen use, with a relative risk for PD of 0.47 (95% CI 0.27--0.8) in caffeine consumers not using hormones and of 1.31 (95% CI 0.75--2.3) in hormone users. Caffeine may be neuroprotective through its antagonist action on the adenosine A~2~A‐receptor ([@bib9020]), which in laboratory studies, modulates dopaminergic neurotransmission ([@bib1960], [@bib1790]) and protects against striatal dopamine loss caused by MPTP ([@bib2060], [@bib1230]). A~2~A‐receptor antagonists are receiving increasing attention as potential treatments, in particular for on/off fluctuations and dyskinesia in combination with levodopa therapy ([@bib2600]), but also as a possible monotherapy in early‐stage PD because of positive results from animal studies and a small clinical trial ([@bib1010], [@bib1220]).

### 6.3.6.3. Alcohol {#s0320}

Alcohol use has been found by some to be inversely associated with PD even after controlling for possible confounding by smoking ([@bib1020], [@bib0730], [@bib1860]). A biologic explanation for this observation has not been articulated. One study found that fewer cases with PD had a diagnosis of alcoholism than controls ([@bib0140]). The variability across studies is great and, overall, the current evidence for an association between alcohol intake and risk of PD is weak. In the Nurses\' Health and the Health Professionals\' cohorts, no association between incidence of PD and overall alcohol consumption was observed ([@bib1060]); however, an inverse association of beer (but not wine or liquor) consumption was seen. Comparison of alcoholics and non‐alcoholics in a large database found comparable PD incidence in both groups ([@bib1070]). Interestingly, in a stratified analysis for men and women separately, male alcoholics had a significantly lower incidence of PD whereas female alcoholics had a twofold increased incidence. Low consumption of alcohol in PD has commonly been attributed to the reserved personality that has been observed prior to PD manifestation ([@bib1690]).

6.3.7. Gender {#s0330}
-------------

As noted above, men appear to be at greater risk of developing PD than are women. This could reflect an intrinsic difference in risk, such as might be due to an X‐chromosome‐linked genetic characteristic or a sex hormone‐related factor. Alternatively, gender‐determined differences in risk factor exposure may be the cause or a combination of biologic predisposition and differences in risk factors might explain this pattern.

[@bib0150] used a population‐based case‐control method to determine whether reproductive factors may influence PD risk in women. Hysterectomy with or without an oophorectomy and early menopause were associated with increased risk of PD (OR = 3.36 and 2.18, respectively) and estrogen use after menopause was inversely associated with PD risk (OR = 0.47), although the latter two differences were not statistically significant. Several subsequent case‐control studies have similarly suggested that factors associated with estrogen deficiency such as hysterectomy and early menopause may increase PD risk ([@bib9000], [@bib2030]). Recently, [@bib1950] found that the association of postmenopausal hormone use with PD risk depended on the type of menopause. Among women with history of a hysterectomy with or without an oophorectomy, estrogen use alone was associated with a 2.6‐fold increased risk and the risk of PD increased with increasing duration of estrogen use. In contrast, among women with natural menopause, no increased risk of PD was observed with hormone use.

Gender may also determine the effects of risk or protective factors associated with PD. Women appear to have different risk profiles to at least some of the exposures linked to PD in men, as discussed in previous sections. Although the explanation for these differences is not known, investigation of the combined effects of risk factors may explain some of these differences. For example, in two prospective cohort studies, PD risk was influenced by the combined effects of caffeine consumption and supplemental estrogen use. Women using supplemental estrogens with low caffeine consumption were at a lower risk of PD, but this effect was attenuated or reversed in women who had a high caffeine consumption and were at higher risk of PD ([@bib0090], [@bib0100]). Future studies including populations of women of sufficient size to allow the separate assessment of risk factors in women will be important to clarify the question of gender and PD risk.

6.4. Gene--environment interactions {#s0340}
===================================

Research in the area of gene--environment interactions is complicated in that multiple genes and various environmental factors may combine to determine the level of risk for PD in any one individual. As described previously, several environmental factors, including pesticide and chemical exposure, have been consistently shown to modify the risk for PD in epidemiologic studies. If PD results from a combination of genetic and environmental factors, then an interaction of genetic factors with certain exposures could result in a high level of disease risk. For example, increased risk from an environmental toxin could be influenced by the genetically determined level of activity of metabolizing enzymes. Few gene--environment interactions have been investigated. One case‐control study suggests that smoking history modifies the effect of family history on the risk for PD, such that the odds ratio is highest in those with a history of smoking and a family history of PD (OR 10.0; [@bib0670]). This is a surprising finding given the increasing body of evidence that smoking is negatively associated with the occurrence of PD.

Other interactions have also been reported, including possible interactions between monoamine oxidase‐B gene polymorphisms and smoking behavior. A reduced risk of PD with increasing number of pack‐years of smoking was found in the presence of the G allele, whereas PD risk decreased with increasing pack‐years smoked in the presence of the A allele ([@bib0420]). Interactions between xenobiotic metabolizing enzyme genotype and pesticide exposure in the risk of PD have also been studied ([@bib1680], [@bib2420]). The association between pesticide exposure and PD may be modified by glutathione transferase P1 polymorphisms ([@bib1680]). In a study of 96 patients and 95 controls, no overall difference in the distribution of glutathione *S*‐transferase (GST) P1 genotypes was found between cases and controls. In those with pesticide exposure, however, the GST P1 AA genotype was associated with the lowest risk for PD. Confirmation of each of these observations in additional populations may provide important clues to disease etiology.

Polymorphisms of many genes have been found to be associated with an increase or decrease in risk for PD in at least one or more studies. Unknown gene--gene or gene--environment interactions may produce misleading results if cases and controls are not appropriately matched, perhaps explaining some of the conflicting data seen in these studies. Whether the inconsistent results obtained to date are due to study design issues or to limited generalizability of the findings to different patient groups is not known.

6.5. The future of Parkinson\'s disease epidemiology {#s0350}
====================================================

An emerging direction of epidemiologic research in PD also deserves mention. Recent work involves investigation of those 'at risk' for PD, before disease is manifest. A variety of disorders may precede formal diagnosis of PD, including olfactory dysfunction, rapid‐eye movement sleep behavior disorders, QT or rate‐corrected QT (QTc) interval prolongation on the electrocardiogram, adiposity and constipation. In vivo imaging of the dopamine transporter with (^99m^Tc)TRODAT‐1 (TRODAT) and olfactory testing have both been proposed as potential biomarkers in PD, and impaired smell recognition correlated with lower TRODAT uptake ([@bib2250]). Rapid‐eye movement sleep behavior disorder is strongly predictive of PD, and RBD patients have been shown to have impaired olfactory function compared to controls ([@bib2290]). In addition to olfactory dysfunction and rapid‐eye movement sleep behavior disorders, a number of patients with PD and multiple system atrophy, have QT or QTc interval prolongation on the electrocardiogram. In one prospective cohort, these findings were highly predictive of PD incidence (LR White, personal communication). Although these QT or QTc interval abnormalities are likely related to autonomic dysfunction, the pathophysiology remains unknown ([@bib0560]). Other characteristics in midlife associated with increased PD risk include increased triceps skinfold thickness ([@bib0020]) and constipation. Men with less than one bowel movement per day at midlife had a 4.1‐fold excess incidence of PD when compared with men with more frequent bowel movements ([@bib0010]). Taken together, these observations suggest that PD may begin decades before nervous system symptoms are observed. PD may be first a disorder of the peripheral autonomic nervous system. If an environmental trigger is involved, the gastrointestinal tract or the olfactory epithelium may be portals of entry. This hypothesis is indirectly supported by neuropathologic findings, suggesting that nigral pathology is a relatively late event in the pathogenesis of PD ([@bib0300]). Further studies to identify those at risk will be essential in determining the causes of PD, and methods for its prevention.

In the next half‐century, the average age of individuals in both developed and developing countries is expected to show a progressive increase. In the USA alone, this phenomenon of population aging is predicted to result in a three‐ to fourfold increase in PD frequency, or several million persons with the disease. The impact of PD can also be expected to affect disease‐associated health expenditures, lost income and personal suffering. As described in this chapter, despite intensive research efforts during the past several decades, the cause (or causes) of typical PD remains unknown. Likely, PD will be understood to be multifactorial, and both genetic and environmental determinants will be important. For example, estimated lifetime penetrance in parkinsonism caused by *LRRK2* in the Ashkenazi Jewish population is only about 30% ([@bib1850]). Both genetic and environmental factors may determine expression of this monogenic form of parkinsonism. Typical PD may similarly be due to many different combinations of genetic or environmental determinants. The investigation of possible gene--environment interaction in PD is just beginning. In the next decade, investigations involving careful characterization of genetic and environmental factors will be essential to defining the causes of PD.

Drs Chade and Kasten are Michael J. Fox Foundation Fellows at The Parkinson\'s Institute. Thank you to Jennifer Wright for editorial assistance.

[^1]: Note: Studies listed should not be compared directly as the age and gender distributions of the underlying populations differ.

[^2]: Normal protein products of *PARK1, 2, 5, 6* and *7* are all likely involved in protein degradation and/or cellular response to toxicant injury or oxidative stress.

[^3]: MPTP, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine; MAO‐B, monoamine oxidase B.
